文献速递妇科

卵巢癌全球趋势与204个国家地区差异

Ovarian cancer global trends and disparities across 204 countries and territories.
PubMed 文献 · Gynecol Oncol · 2026-07-16

基于全球疾病负担2023数据,分析204个国家地区1990至2023年卵巢癌发病、死亡与伤残调整寿命年。全球发病数从158,403增至338,615,死亡数从106,301增至220,979,年龄标化死亡率年均下降0.44%。早发性卵巢癌发病率年均上升0.26%,死亡率与发病率比值与社会经济发展负相关,低发展地区差异扩大。

要点

  • 全球卵巢癌发病与死亡绝对数增加,但年龄标化死亡率年均下降0.44%。
  • 早发性卵巢癌(<50岁)发病率年均上升0.26%。
  • 低发展地区死亡率与发病率比值更高且差异扩大。

核心结论

  • 全球卵巢癌负担持续增加,差异持续存在并在部分低发展地区扩大。

研究设计与样本

  • 基于全球疾病负担2023估计,分析204个国家地区1990至2023年卵巢癌数据。
  • 早发性卵巢癌定义为诊断时年龄小于50岁。
  • 采用Joinpoint回归评估时间趋势,以平均年度百分比变化汇总。
  • 使用死亡率与发病率比值和社会人口指数评估差异。
  • 利用全球疾病负担预测模型推算至2050年。

主要发现

  • 全球发病数从1990年158,403例增至2023年338,615例。
  • 死亡数从1990年106,301例增至2023年220,979例。
  • 年龄标化死亡率从6.29/10万降至5.95/10万,年均变化-0.44%(95%CI -0.52%至-0.36%)。
  • 早发性卵巢癌发病率年均上升0.26%(95%CI 0.04%至0.48%)。
  • 死亡率与发病率比值与社会经济发展呈负相关(R2=0.52),前沿分析显示低发展地区差异扩大。

关键数值与推荐

  • 年龄标化死亡率年均变化-0.44%(95%CI -0.52%至-0.36%)。
  • 早发性卵巢癌发病率年均变化0.26%(95%CI 0.04%至0.48%)。
  • 死亡率与发病率比值与社会经济发展负相关(R2=0.52)。
  • 2023年高体重指数归因于6.37%的卵巢癌死亡。
  • 2050年预测年发病402,549例,年死亡259,304例。

临床怎么用

  • 关注全球卵巢癌负担增加趋势,尤其早发性病例上升。
  • 在低发展地区加强卵巢癌防控以缩小差异。
  • 将高体重指数作为卵巢癌死亡的可干预因素。
  • 为2050年发病与死亡增长提前规划医疗资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ovarian cancer remains the deadliest gynecological malignancy and is frequently diagnosed at advanced stages. Updated global assessments are needed to quantify recent trends, forecast future disease burden, and characterize geographic disparities in outcomes. METHODS: We analyzed Global Burden of Disease 2023 estimates for ovarian cancer across 204 countries and territories from 1990 through 2023. Incident cases, deaths, disability-adjusted life years, and age-standardized incidence and mortality rates were evaluated. Early-onset ovarian cancer was defined as diagnosis before 50 years of age. Temporal trends were assessed using Joinpoint regression and summarized as average annual percentage changes. Disparities were examined using mortality-to-incidence measures, the Socio-Demographic Index. Global Burden of Disease forecasts were used to project incidence and mortality through 2050. RESULTS: Globally, incident cases increased from 158,403 in 1990 to 338,615 in 2023. Deaths increased from 106,301 to 220,979, while the age-standardized mortality rate declined modestly from 6.29 to 5.95 per 100,000, corresponding to an average annual change of -0.44% (95% confidence interval, -0.52% to -0.36%). Early-onset incidence increased by an average of 0.26% annually (95% confidence interval, 0.04% to 0.48%). Mortality relative to incidence was inversely correlated with socioeconomic development (R2 = 0.52), and frontier analyses indicated widening disparities in lower-development settings. High body mass index accounted for 6.37% of ovarian cancer deaths in 2023. By 2050, annual cases are projected to reach 402,549 and deaths to reach 259,304. CONCLUSION: Ovarian cancer burden is increasing worldwide, with persistent and, in some settings, widening disparities.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Leite LF, da Conceição LD, de Almeida LFC, et al. Ovarian cancer global trends and disparities across 204 countries and territories. Gynecol Oncol. 2026. PMID: 42456484. doi:10.1016/j.ygyno.2026.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。